Retension Pharmaceutical Overview
- Year Founded
-
2023
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
RTSN
- Share Price
-
$13.40
- (As of Wednesday Closing)
Retension Pharmaceutical General Information
Description
Retension Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure.
Contact Information
Website
www.retensionpharmaceuticals.comCorporate Office
- 1104 West Broad Street
- Suite 1029
- Falls Church, VA 22046
- United States
Corporate Office
- 1104 West Broad Street
- Suite 1029
- Falls Church, VA 22046
- United States
Retension Pharmaceutical Timeline
Retension Pharmaceutical Stock Performance
As of 18-Nov-2026, Retension Pharmaceutical’s stock price is $13.40. Its current market cap is $116M with 8.33M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.40 | $11.41 | $9.66 - $18.64 | $116M | 8.33M | 148K | -$2.61 |
Retension Pharmaceutical Financials Summary
As of 30-Jun-2026, Retension Pharmaceutical has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| EBITDA | (12,559) | (6,881) | (2,266) |
| Net Income | (11,941) | (6,301) | (1,910) |
| Total Assets | 16,127 | 21,445 | 8,370 |
| Total Debt | 0 | 0 | 0 |
Retension Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Retension Pharmaceutical Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Retension Pharmaceutical Patents
Retension Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026107071-A1 | Combination therapy | Pending | 14-Nov-2024 | ||
| US-20260132135-A1 | Crystalline form | Pending | 14-Nov-2024 | ||
| WO-2026107107-A1 | Crystalline form of a pde5 inhibitor | Pending | 14-Nov-2024 | ||
| US-12258350-B1 | Crystalline forms of 4-ethoxy-n-(2-methoxyethyl)-n-methyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5, 1-f][1,2,4]triazin-2-yl)benzenesulfonamide | Active | 14-Nov-2024 | C07D487/04 |
Retension Pharmaceutical Signals
Retension Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Retension Pharmaceutical FAQs
-
When was Retension Pharmaceutical founded?
Retension Pharmaceutical was founded in 2023.
-
Where is Retension Pharmaceutical headquartered?
Retension Pharmaceutical is headquartered in Falls Church, VA.
-
What is the size of Retension Pharmaceutical?
Retension Pharmaceutical has 12 total employees.
-
What industry is Retension Pharmaceutical in?
Retension Pharmaceutical’s primary industry is Drug Discovery.
-
Is Retension Pharmaceutical a private or public company?
Retension Pharmaceutical is a Public company.
-
What is Retension Pharmaceutical’s stock symbol?
The ticker symbol for Retension Pharmaceutical is RTSN.
-
What is the current stock price of Retension Pharmaceutical?
As of 18-Nov-2026 the stock price of Retension Pharmaceutical is $13.40.
-
What is the current market cap of Retension Pharmaceutical?
The current market capitalization of Retension Pharmaceutical is $116M.
-
What is Retension Pharmaceutical’s annual earnings per share (EPS)?
Retension Pharmaceutical’s EPS for 12 months was -$2.61.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process